文献类型：期刊文献

英文题名：Antidiabetic activity of lipophilic (-)-epigallocatechin-3-gallate derivative under its role of α-glucosidase inhibition

作者：Li, Ting; Liu, Jianwen; Zhang, Xiaodong; Ji, Guang

机构：[1]E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China;[2]Shanghai Univ Tradit Chinese Med, Longhua Hosp, Lab Liver Dis, Shanghai 200032, Peoples R China

年份：2007

卷号：61

期号：1

起止页码：91

外文期刊名：BIOMEDICINE & PHARMACOTHERAPY

收录：;WOS:【SCI-EXPANDED(收录号:WOS:000244918900012)】；

语种：英文

外文关键词：alpha-glucosidase inhibitor; blood glucose; postprandial hyperglycemia

摘要：(-)-Epigallocatechin-3-gallate (EGCG), a component of catechins, has been shown to reduce blood glucose levels. In the present study, we investigated the antidiabetic activity and its mechanism of lipophilic EGCG derivative (L-EGCGd) in streptozotocin (STZ)-induced diabetic rats. L-EGCGd was chemically modified from traditional hydrophilic EGCG. After 30 days treatment, plasma levels of glucose were significantly reduced by 40.5 +/- 7.0% and 17.0 +/- 2.8% in groups administered 50 or 25 mg kg(-1) d(-1) L-EGCGd, respectively, as compared with that in the diabetic control group. Lipid metabolites, such as total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDLC) were effectively attenuated by L-EGCGd administration, but plasma HDLC levels did not change significantly. The oral glucose tolerance test (OGTT) greatly revealed the improved ability of glucose tolerance with treatment of L-EGCGd. L-EGCGd only retarded the postprandial rise in blood glucose with sucrose loading but not glucose loading. And activity of alpha-glucosidase was inhibited by 50% at the concentration of 246.6 mu g ml(-1) L-EGCGd. As a result, we first demonstrated that the purified form of compound L-EGCGd possessed the hypoglycemic effect under its role of alpha-glucosidase inhibition, and therefore should be possibly accepted as an alternative oral medication protecting patients against postprandial hyperglycemic toxicity on the treatment of diabetes and its complications. (c) 2006 Elsevier Masson SAS. All rights reserved.